Oaklander welcomed the news of the approval of the new vaccine, saying that more adults should be vaccinated against shingles. In the United States alone, there are an estimated 1 million cases of shingles a year, and one in three people can expected to develop the condition during their lifetime.
6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
BMO Capital Markets reiterated a âbuyâ rating and issued a $80.00 price target on shares of Xilinx in a research note on Wednesday, October 18th. Goldman Sachs Group upgraded shares of Xilinx from a âneutralâ rating to a âbuyâ rating in a research note on Friday.